

Follow-up

The standard study duration is at least 12 weeks (excluding the screening period of 16 days). During this period one visit per week is planned in the first 4 weeks, and a final study visit in week 12.

Interested?

If you are interested, please reach out to your physician or contact the study team mentioned in this leaflet.

This clinical trial has been approved by the Federal Agency for Medicines and Health Products and has received a favorable opinion from the Ethics Committee of UZA.

MATTERS study

This clinical trial will evaluate whole-body hyperthermia in combination with chemotherapy with a new medical device for the treatment of patients with advanced pancreatic cancer.

Principal investigators

- Prof. dr. Marc Peeters
- Prof. dr. Dirk Ysebaert
- Dr. Vera Saldien

Contact UZA

Study coordinator UZA: Peggy De Clercq
tel +32 821 53 07
fax +32 821 58 59
peggy.declercq@uza.be

This folder contains general information and is intended to supplement the discussion with your healthcare provider.

UZA / Drie Eikenstraat 655 / 2650 Edegem
Tel +32 3 821 30 00 / www.uza.be
Follow us on Facebook  and Twitter 

MATTERS study

Information leaflet

© UZA, Juni 2022. Niets uit deze brochure mag worden overgenomen zonder uitdrukkelijke toestemming. MOCA-2564693



The MATTERS study examines whole-body hyperthermia in combination with chemotherapy. We use a new medical device, specifically for the treatment of patients with pancreatic cancer in an advanced stage.

Clinical trial

A clinical trial investigates new potential treatments. These treatments can be beneficial for participating patients.

Whole-body hyperthermia - innovative application for existing cancer treatment

Hyperthermia treatment is a procedure in which the body temperature is raised above the normal temperature for a certain period. This heating boosts the immune system and helps the body to fight cancer cells.

The use of heat to treat disease is not new, as it dates back to the early Egyptian times. Over the past 100 years, hyperthermia treatment has been reintroduced into the medical world. In some European countries, such as Germany or the Netherlands, hyperthermia is part of the standard care for certain diseases.

Previous clinical research has demonstrated that hyperthermia may have a positive outcome when treating cancer.



Besides boosting the immune system, hyperthermia treatment also enhances the effectiveness of radiotherapy and chemotherapy and has a direct cell killing effect. This treatment may potentially prolong life expectancy and/or improve quality of life of the treated patients.

MATTERS clinical trial

A study on whole-body hyperthermia for cancer treatment

This trial will use the HyperTherm device to deliver a whole-body hyperthermia treatment to patients with advanced pancreatic cancer in combination with chemotherapy. This method has already provided promising results in pre-clinical studies.

This is a first-in-human trial, meaning that this is the first time this specific device is being used to apply whole-body hyperthermia in human cancer patients.

The research goals of this clinical trial are to demonstrate safety and efficacy of this specific device.

Screening

The study team will assess whether you meet the criteria for participating in this trial. You will need to visit the hospital 1 or 2 times to complete the screening.

Treatment

The HyperTherm device is designed to raise the body temperature for a certain period in a safe and controlled manner to 41.5°C. The main objective is to assess the safety of different durations (2, 4 or 6 h) and repetitions (once a week for 3 weeks).

Different sensors are placed on the body to monitor the vital signs and to ensure your safety at all times. For your comfort, the procedure is performed under full anesthesia. After each treatment session, you will remain in the hospital for 2 days for observation.

This study is conducted in collaboration with ElmediX.